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Abstract
Background: The Hedgehog signaling pathway functions as an organizer in embryonic development. Recent
studies have demonstrated constitutive activation of Hedgehog pathway in various types of malignancies.
However, it remains unclear how Hedgehog pathway is involved in the pathogenesis of osteosarcoma. To explore
the involvement of aberrant Hedgehog pathway in the pathogenesis of osteosarcoma, we investigated the
expression and activation of Hedgehog pathway in osteosarcoma and examined the effect of SMOOTHENED (SMO)
inhibition.
Results: To evaluate the expression of genes of Hedgehog pathway, we performed real-time PCR and
immunohistochemistry using osteosarcoma cell lines and osteosarcoma biopsy specimens. To evaluate the effect of
SMO inhibition, we did cell viability, colony formation, cell cycle in vitro and xenograft model in vivo. Real-time PCR
revealed that osteosarcoma cell lines over-expressed Sonic hedgehog, Indian hedgehog, PTCH1, SMO, and GLI. Real-
time PCR revealed over-expression of SMO, PTCH1, and GLI2 in osteosarcoma biopsy specimens. These findings
showed that Hedgehog pathway is activated in osteosarcomas. Inhibition of SMO by cyclopamine, a specific
inhibitor of SMO, slowed the growth of osteosarcoma in vitro. Cell cycle analysis revealed that cyclopamine
promoted G1 arrest. Cyclopamine reduced the expression of accelerators of the cell cycle including cyclin D1,
cyclin E1, SKP2, and pRb. On the other hand, p21
cip1 wprotein was up-regulated by cyclopamine treatment. In
addition, knockdown of SMO by SMO shRNA prevents osteosarcoma growth in vitro and in vivo.
Conclusions: These findings suggest that inactivation of SMO may be a useful approach to the treatment of
patients with osteosarcoma.
Background
Osteosarcoma is the most common primary bone malig-
nant tumor occurring mainly in children [1]. After
initial diagnosis is made by biopsy, treatment consists of
preoperative chemotherapy, followed by definitive sur-
gery and postoperative chemotherapy. Survival has
improved over the past several decades. Indeed, patients
with non-metastatic disease have a 70% chance of long-
term survival. Unfortunately, patients with metastatic
disease at diagnosis and those who have recurrent dis-
ease have a poor prognosis, with only 20% surviving at 5
years, indicating that new therapeutic options for them
need to be actively explored. In cancer cells,
dysregulation of cell division and apoptotic processes
contribute to both drug resistance and metastatic poten-
tial [2,3]. It has been reported that inactivation of the
cell cycle regulatory pathway centered around the Rb
gene is a critical step in the pathogenesis of osteosar-
coma [4]. Although such dysregulation may constitute a
potent source of new therapeutic targets, the molecular
mechanisms of regulation of osteosarcoma cell prolifera-
tion are largely unknown.
Hedgehog (Hh) pathway has been implicated in differ-
ent aspects of animal development, acting through sev-
eral components, including the transmembrane proteins
PATCHED (PTCH1) and SMOOTHENED (SMO), to
activate the GLI zinc-finger transcription factors [5,6].
Hh pathway is critical for many processes during
embryonic and postnatal development, including prolif-
eration, differentiation, specification of cell fate,
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and familial mutations in the Hh pathway genes,
PTCH1, suppressor-of-fused, and SMO, leading to ele-
vated expression of downstream target genes including
GLI, have been reported in basal cell carcinoma and the
pediatric brain tumor medulloblastoma [8,9]. In addi-
tion, the growth of many cancers has been suggested to
depend on continuous Hh pathway even in the absence
of activating mutations in the pathway (reviewed in
ref. [10]).
To explore the involvement of Hh pathway in the
pathogenesis of osteosarcoma, we investigated the
expression and activation of the Hh pathway genes in
osteosarcoma and examined the effect of inhibition of
SMO by cyclopamine, a specific inhibitor of SMO [11]
or SMO shRNA.
Results
Over-expression of Hh-GLI pathway molecules in
osteosarcoma
To examine the role of Hhï¿½GLI pathway in osteosar-
coma, we tested for the expression of Hh in osteosar-
coma cell lines. Real-time PCR revealed that 4 of 5
human osteosarcoma cell lines increased Sonic Hedgehog
(SHH) 2.1- to 18.8-fold (Fig. 1). In addition, 5 of 5
osteosarcoma cell lines increased Desert Hedgehog 1.3-
to 24.4-fold (Fig. 1). To further examine Hh pathway
molecules expression, we performed real-time PCR for
Hh receptors and Hh target genes. PTCH1 was up-regu-
lated 2.7-to 65.8-fold in 5 of 5 human osteosarcoma cell
lines. SMO was up-regulated 2.1-to 5.8-fold in 4 of 5
human osteosarcoma cell lines. SMO was up-regulated
2.1-to 5.8-fold in 4 of 5 human osteosarcoma cell lines.
GLI1 was up-regulated 2.5-to 8.9-fold in 5 of 5 human
osteosarcoma cell lines. GLI2 was up-regulated 1.2-to
9.9-fold in 5 of 5 human osteosarcoma cell lines. To
extend these findings, we performed immunocytochem-
istry for SMO and GLI2, and found that only osteosar-
coma cells expressed detectable levels of SMO and
GLI2. GLI2 was located in the nuclei of osteosarcoma
cells (see additional file 1). We next examined SMO
expression in osteosarcoma patient’ biopsy specimens.
Real-time PCR revealed that 9 of 9 human biopsy speci-
mens of osteosarcoma increased SMO 1.44- to 55.5-fold
(Fig. 2). In addition, real-time PCR revealed that expres-
sion of PTCH1 was increased in 8 of 9 patients’ biopsy
samples 2.44- to 29.4-fold (Fig. 2). GLI2 was up-regu-
lated 2.5-to 58.4-fold in 9 of 9 human biopsy specimens
of osteosarcoma (Fig. 2). Of most importance was the
finding that markers of active Hhï¿½GLI signaling, GLI2
and PTCH1 were consistently up-regulated in the exam-
ined osteosarcoma cells, demonstrating the aberrant
Hh-GLI pathway activation [12-14]. Our findings sug-
gest that Hh-GLI signaling is active in osteosarcomas.
Inhibition of SMO prevents osteosarcoma growth in vitro
To determine whether activation of Hh-GLI signaling is
required for osteosarcoma cell growth, we used cyclopa-
mine, a pharmacological agent known to effectively
block Hh-GLI signaling by inhibiting SMO activation
[11]. We performed real-time PCR to determine
whether cyclopamine effectively inhibited the expression
of the GLI target gene PTCH1 and GLI2 [14]. Cyclopa-
mine at 20 μM reduced mRNA levels of PTCH1 and
GLI2 in osteosarcoma cells by more than 60%, consis-
tent with the expected down-regulation of Hh-GLI sig-
naling (Fig. 3A). As cyclopamine was used to prevent
cancer cells growth at 10 to 20 μM [15-17] we decided
20 μM was appropriate concentration for osteosarcoma.
MTT assay showed that cyclopamine slowed the growth
of HOS and 143B in dose-dependent fashion (Fig. 3B).
On the other hand, MTT assay showed that prolifera-
tion of osteosarcoma cells was enhanced by SHH. We
next used a clonogenic assay to determine whether cells
capable of forming anchorage-independent colonies
were depleted by cyclopamine. This assay revealed
cyclopamine reduced colony formation in soft agar (Fig.
3C). These findings suggest that inhibition of SMO
inhibited osteosarcoma growth in vitro.
Hh signaling regulates cell cycle of osteosarcoma
We examined cell cycle characteristics by flow cytometry.
Of 143B cells cultured without cyclopamine, 39.8% of
cells were in G1 phase, while 56.6% of cells were in G1
phase following treatment with cyclopamine. In the case
of HOS cells were cultured without cyclopamine, 55.4%
cells were in G1 phase. On the other hand, when cul-
tured with cyclopamine, 72.3% of cells were in G1 phase
(Fig. 4A). These findings suggested that cyclopamine pro-
moted G1 arrest. We then examined the transcription of
cell cycle-related genes. Real-time PCR revealed that
cyclopamine prevented the transcription of accelerators
of the cell cycle including cyclin D1, cyclin E1, SKP2,a n d
NMYC (Fig. 4B). In mammalian cells, cyclin D, cyclin E,
and p21
cip1 are short-lived proteins that are controlled by
ubiquitin-dependent proteolysis. We performed western
blot analysis to determine protein levels, and found that
cyclopamine reduced the levels of expression of cyclin D1
and cyclin E1 proteins. Cyclopamine also reduced the
levels of expression of cyclin D1, cyclin E1, pRb, and
SKP2 proteins (Fig. 4C). We next examined the expres-
sion of p21
cip1, and found that p21
cip1 protein was up-
regulated by cyclopamine treatment (Fig. 4C). These find-
ings suggested that cyclopamine promoted G1 arrest by
inhibition of G1-S phase progression. These findings sug-
gest that inhibition of SMO inhibited osteosarcoma
growth via cell cycle regulation.
Knock down of SMO prevents osteosarcoma growth in vivo
To confirm the effect of SMO suppression, we examined
the effect of SMO shRNA. 143B was transfected with
Hirotsu et al. Molecular Cancer 2010, 9:5
http://www.molecular-cancer.com/content/9/1/5
Page 2 of 14Figure 1 Expression of activated Hh-GLI pathway molecules. Total RNA extracted from osteosarcoma cell lines were used for real-time PCR.
Real-time PCR revealed that 4 of 5 human osteosarcoma cell lines increased Sonic Hedgehog (SHH) 2.1- to 18.8-fold (Fig. 1). In addition, 5 of 5
osteosarcoma cell lines increased Desert Hedgehog 1.3- to 24.4-fold (Fig. 1). To further examine Hh pathway molecules expression, we performed
real-time PCR for Hh receptors and Hh target genes. PTCH1 was up-regulated 2.7-to 65.8-fold in 5 of 5 human osteosarcoma cell lines. SMO was
up-regulated 2.1-to 5.8-fold in 4 of 5 human osteosarcoma cell lines. SMO was up-regulated 2.1-to 5.8-fold in 4 of 5 human osteosarcoma cell
lines. GLI1 was up-regulated 2.5-to 8.9-fold in 5 of 5 human osteosarcoma cell lines. GLI2 was up-regulated 1.2-to 9.9-fold in 5 of 5 human
osteosarcoma cell lines. The comparative Ct (ΔΔCt) method was used to determine fold change in expression using bII-microglobulin, GAPDH or
ACTB. Each sample was run minimally at three concentrations in triplicate (error bar means S.D.). The experiment was triplicate with similar
results.
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Page 3 of 14Figure 2 Activation of Hh pathway in patient’ biopsy samples. Real-time PCR revealed that 9 of 9 human biopsy specimens of
osteosarcoma increased SMO 1.44- to 55.5-fold. Real-time PCR revealed that expression of PTCH1 was increased in 8 of 9 patients’ biopsy
samples 2.44- to 29.4-fold. GLI2 was up-regulated 2.5-to 58.4-fold in 9 of 9 human biopsy specimens of osteosarcoma. The comparative Ct (ΔΔCt)
method was used to determine fold change in expression using bII-microglobulin, ACTB, and GAPDH. Each sample was run minimally at three
concentrations in triplicate (error bar means S.D.). The experiment was triplicate with similar results.
Hirotsu et al. Molecular Cancer 2010, 9:5
http://www.molecular-cancer.com/content/9/1/5
Page 4 of 14Figure 3 Inhibition of Hh pathway prevents osteosarcoma growth in vitro. A, We performed real-time PCR to determine which
concentration of cyclopamine effectively inhibited Hh-GLI activity in osteosarcoma cells, and then measured the expression of the Hh-GLI
pathway target PTCH1 and GLI2. Cyclopamine at 20 μM reduced mRNA levels of PTCH1 in 143B cell (error bar means S.D.). The comparative Ct
(ΔΔCt) method was used to determine fold change in expression using ACTB. Each sample was run minimally at three concentrations in triplicate
(error bar means S.D.). The experiment was triplicate with similar results. B, Growth of viable 143B and HOS cells over 3 days was slowed in dose-
dependent fashion by cyclopamine treatment. The experiment was triplicate with similar results. C, Colony formation assay revealed cyclopamine
reduced colony formation in soft agar. The experiment was triplicate with similar results. (*: P < 0.01) (error bar means S.D.)
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Page 5 of 14Figure 4 Cyclopamine treatment promotes G1 arrest. A, HOS and143B cells were treated with 10 μM cyclopamine. After 48-hour treatment
cells were collected and subjected to cell cycle analysis. When 143B cells were cultured without cyclopamine, 39.8% of cells were in G1 phase.
On the other hand, when cultured with cyclopamine, 56.6% of cells were in G1 phase. In the case of HOS cells cultured without GSI, 55.4% of
cells were in G1 phase, while 72.3% of cells were in G1 phase when treated with cyclopamine (error bar means S.D.). B, Real-time PCR was
performed to quantify mRNAs of cell cycle related genes. Twenty-four-hour treatment with cyclopamine reduced levels of cyclin D1, Cyclin E1,
SKP2, and NMYC transcription (error bar means S.D.). The comparative Ct (ΔΔCt) method was used to determine fold change in expression using
bII-microglobulin and GAPDH. Each sample was run minimally at three concentrations in triplicate (error bar means S.D.). The experiment was
triplicate with similar results. C, Western blot analysis of levels of cell cycle-related genes. Forty-eight-hour treatment with cyclopamine reduced
levels of expression of cyclin D1, cyclin E1, SKP2, and phosphprylated RB (pRb) proteins. Expression of P21
cip1 protein was upregulated by
cyclopamine treatment. The experiment was triplicate with similar results (cyclopamine: 10 μM).
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Page 6 of 14control shRNA or SMO shRNA. SMO shRNA reduced
the expression of SMO mRNA (Fig. 5A). MTT assay
revealed that knock-down of SMO prevented osteosar-
coma growth in vitro (Fig. 5A). We next used a clono-
genic assay to determine whether cells capable of
forming anchorage-independent colonies were depleted
by SMO shRNA. This assay revealed SMO shRNA
reduced colony formation in soft agar (Fig. 5B). These
findings show that suppression of SMO prevents osteo-
sarcoma growth in vitro. We then examined the tran-
scription of cell cycle-related genes. Real-time PCR
revealed that SMO shRNA prevented the transcription
of accelerators of the cell cycle including cyclin D1,
cyclin E1, SKP2,a n dE2F1 (see additional file 2). To
examine the in vivo effect of SMO shRNA, nude mice
were inoculated with control shRNA or SMO shRNA
transfected 143B osteosarcoma cells intradermally.
Results demonstrated significant inhibition of tumor
growth SMO shRNA versus control shRNA (Fig. 6A, B).
Kaplan-Meier analysis showed that SMO shRNA con-
ferred a significant survival benefit (Fig. 6B). Next, we
performed real-time PCR using formed tumors. Real-
time PCR revealed that transcription of GLI1, GLI2, and
PTCH1 was decreased in tumors formed by SMO
shRNA-transfected 143B. These findings showed that
SMO shRNA prevented the transcription of Hh target
genes in vivo. In addition, SMO shRNA prevented the
transcription of accelerators of the cell cycle including
cyclin E1, SKP2,a n dE2F1 (see additional file 3). Histo-
logical analysis indicated that SMO shRNA prevented
cell proliferation. The control tumors exhibited a num-
b e ro fc e l l sp o s i t i v ef o rK i 6 7 ,am a r k e ro fc e l lp r o l i f e r a -
tion. In contrast, SMO shRNA transfected tumors
exhibited little evidence of proliferation, as evidenced by
lack of Ki67 positivity. The number of Ki67-positive
cells was decreased to 30% of control revel by SMO
shRNA (Fig. 6C). These findings suggest that inhibition
of SMO prevents osteosarcoma growth by cell cycle reg-
ulation in vivo.
Discussion
Although the role of Hh signaling in various cancers
[18-21], it’s role in the pathogenesis of osteosarcoma
has not been reported. In the present study, we found
that Shh, Dhh, PTCH1, SMO, GLI1 and GLI2 transcripts
were over-expressed in osteosarcoma cell line. In addi-
tion, SMO, PTCH1,a n dGLI2 were over-expressed in
osteosarcoma biopsy specimens’. In general, it is
accepted that enhanced Hh pathway activation leads to
downstream expression of target genes including
PTCH1 and GLI, and hence, the levels of these tran-
scripts are often used as surrogate markers of Hh path-
way activity [22]. In addition, SHH promoted
osteosarcoma cells proliferation. Our findings suggest
that Hh pathway is activated in osteosarcomas. On the
other hand, GLI1 was down-regulated in human osteo-
sarcoma biopsy specimens (data not shown). The reason
for GLI1 down-regulation could not be determined. One
possibility is that the GLI1 promoter is inactivated in
human osteosarcomas by epigenetic modification. We
found that GLI1 promoter contains a CG-rich region.
Wong et al. reported that Hh pathway activity down-
stream of SMO is mediated by GLI2 [23]. These data
suggest that Hh activity down-stream of SMO is
mediated by GLI2 instead of GLI1 in osteosarcoma.
SMO is a central transducer of the Hh signal and
important anticancer drug target [11,14,19,22,24-33].
Warzecha et al reported that cyclopamine is able to
inhibit proliferation of osteosarcoma cell lines [34]. In
agreement with their findings, our results showed that
inhibition of SMO by cyclopamine or SMO shRNA is
efficient in suppressing tumourigenic properties of
osteosarcoma cells both in vitro and in vivo. We used
cyclopamine to inhibit SMO in xenograft model at first.
We performed that treatment with 25 mg/kg cyclopa-
mine reduced numbers of ki67-positive cells (see addi-
tional file 4). These findings suggest that inhibition of
SMO prevents osteosarcoma growth by cell cycle regula-
tion in vivo. Although it appeared that osteosarcoma
growth was prevented by cyclopamine, all mice died for
undetermined reasons by 1 month after cyclopamine
treatment (data not shown). We next performed 10 mg/
kg cyclopamine treatment, and found no difference in
osteosarcoma growth between cyclopamine treatment
and the control group (data not shown). Unfortunately,
a therapeutic dose of this agent in the 143B xenograft
model could not be obtained. It has been reported that
cyclopamine might not be a good candidate for a drug
in the treatment of malignant tumors because it had
several serious side effects in young mice, including
weight loss and dehydration, suggesting that it may not
be possible to achieve a therapeutic dose in our xeno-
graft model system [28,35]. In efforts to solve these pro-
blems, we used SMO shRNA. SMO shRNA inhibited
osteosarcoma growth. Kaplan-Meier analysis showed
that SMO shRNA conferred a significant survival bene-
fit. It was reported that administration of RNAi resulted
in silencing of the target genes in vivo [36-41]. These
findings demonstrate the therapeutic potential of SMO
shRNA for the treatment of osteosarcoma. Although
SMO is the major signal transducer of the Hh pathway,
SMO inhibition suppresses tumorigenesis by down-reg-
ulation of b-catenin mediated Wnt signaling [42]. It was
reported that deregulation of b-catenin signaling is
implicated in the pathogenesis of osteosarcoma [43,44].
Further examination might be needed the relationship
between SMO inhibition and Wnt-b-catenin signaling in
osteosarcoma.
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Page 7 of 14Figure 5 Knock down of SMO by SMO shRNA prevents osteosarcoma growth in vitro. A, Real-time PCR revealed that SMO shRNA
effectively knock down SMO mRNA. (error bar means S.D.). The comparative Ct (ΔΔCt) method was used to determine fold change in expression
using ACTB. Each sample was run minimally at three concentrations in triplicate (error bar means S.D.). The experiment was triplicate with similar
results. B, Growth of viable 143B cells over 4 days was slowed by SMO shRNA. The experiment was triplicate with similar results. C, Colony
formation assay revealed that SMO shRNA reduced colony formation in soft agar. The experiment was triplicate with similar results. (*: P < 0.01)
(Error bar means S.D.)
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Page 8 of 14Figure 6 SMO shRNA prevents osteosarcoma xenograft growth in vivo and prolongs survival.A ,SMO shRNA or control shRNA transfected
143B cells (1 × 10
6) were inoculated subcutaneously. Established 143B tumors were measured. The tumor volume at day 7 was set at 1, and
tumor volumes at subsequent time points were calculated. SMO shRNA inhibited tumor growth at 8 weeks compared to control shRNA. B,
Kaplan-Meier survival curves from SMO shRNA groups and control shRNA. Kaplan-Meier analysis showed that SMO shRNA conferred a significant
survival benefit (n = 6, p < 0.05). C, Immunohistochemical examination of ki67 was performed in xenograft tumors. SMO shRNA decreased SMO
RNA in vivo. Ki67 staining revealed that proliferation of osteosarcoma cells was decreased by GSI treatment. The number of Ki67-positive cells
was decreased to 30% of control revel by SMO shRNA (error bar means S.D.) (*: P < 0.01).
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Page 9 of 14Cyclopamine promoted G1 arrest in osteosarcoma in
vitro. We also found that cyclopamine treatment regu-
lated the expression of cell cycle regulators. Quantitative
real-time PCR and western blot analysis revealed that
cyclin D1, E1, SKP2, and pRB were down-regulated
upon SMO inhibition with cyclopamine. Cyclin D1,
cyclin E1, SKP2, and pRb have been reported to pro-
mote G1-S phase progression [45-48]. Our findings sug-
gest that cyclopamine promoted cell cycle arrest via
down-regulation of cyclins and pRb. It has been
reported that cyclin D1 and cyclin E1 are direct targets
of Hh signaling [49,50]. GLI2 mediated the mitogenic
effects of Shh by transcriptional activation of cyclin D1
and cyclin D2 in developing hair follicles [51]. Our find-
ings are consistent with the results of these previous
studies. We showed that cyclopamine decreased the
transcription of SKP2. The relationship between Hh sig-
naling and SKP2 have not been reported. We attempted
to find a GLI binding site (GACCACCCA) in the -1000
t o+ 2 0r e g i o no ft h e5 ’ flanking sequence of SKP2,b u t
found no GLI binding consensus sequence. These find-
i n g ss u g g e s tt h a tt r a n s c r i p t i o no fSKP2 might not be
regulated by GLI. It has been reported that the SKP2
gene contains a functional E2F response element and is
transcribed by E2F1 [52]. E2F1 is an early transcriptional
target of GLI2 [53]. In addition, E2F1 transcription is
activated by Rb phosphorylation. Our findings suggest
that down-regulation of E2F1 and pRb indirectly
reduced the transcription of SKP2.I na d d i t i o n ,w e
showed that cyclopamine treatment promoted p21
Cip1
up-regulation. p21
cip1 can bind to various cyclin depen-
dent kinases and that it inhibits their kinase activity.
Our findings suggest that inhibition of the Hh pathway
reduces the expression of the SKP2 subunit of the ubi-
quitin-ligase complex SCF
SKP2, which in turn inhibit
proteasomeï¿½mediated degradation of p21
Cip1 and pro-
mote cell cycle arrest.
It has been reported that cyclopamine treatment
induced apoptosis in tumor cells [20,32,54]. We per-
formed apoptosis assay, but could not detect apoptosis
of 143B osteosarcoma cell line (data not shown). This
finding may be the result of differences in cell viability
between osteosarcoma and other cancer cell lines.
Several key signalling pathways, such as Hedgehog,
Notch, Wnt and BMP-TGFbeta-Activin (bone morphoge-
netic protein-transforming growth factor-beta-Activin),
are involved in most processes essential to the proper
development of an embryo. It is also becoming increas-
ingly clear that these pathways can have a crucial role in
tumorigenesis (reviewed in [19]). We previously reported
that activation of Notch signaling promote the progression
of human osteosarcoma [55]. Additionally, some recent
reports have provided evidence for direct interaction or
cross-talk between these pathways (reviewed in [56]).
Further examination should be performed to elucidate
these pathways interaction in osteosarcoma pathogenesis.
Several recent papers have demonstrated that anti-
tumor effect by SMO inhibitors are mostly due to their
effect on stromal cells [57,58]. On the other hand some
papers have reported that Hh signaling pathway is acti-
vated in cancer cells [14,17,21,23,59]. Although, there is
a possibility that anti-osteosarcoma effect by cyclopa-
mine was partially dependent to the effect on bone mar-
row stromal cell, anti-tumor effect of SMO shRNA
revealed that inactivation of SMO directly inhibits
osteosarcoma proliferation in vitro and in vivo.
The hypothesis that malignant tumours are generated
by rare populations of Tumour-initiating cells (TIC),
also called cancer stem cells, that are more tumouri-
genic than other cancer cells has gained increasing cre-
dence [31,60]. Some reports have shown the existence
of TICs in bone and soft tissue sarcomas [61-65]. Magali
et al. reported that loss of Smo causes depletion of TICs
whereas constitutively active Smo augments TICs num-
ber and accelerates disease [20,66]. These data suggest
that inhibition of Hh pathway might affect the prolifera-
tion of TICs of osteosarcoma.
In conclusion, our findings demonstrate that the Hh
pathway is functionally activated in osteosarcoma. This
novel finding improves understanding of osteosarcoma
and may be important in understanding the proliferation
of osteosarcoma cells. Our findings suggest that inacti-
vation of SMO may be an attractive target for the treat-
ment of patients with osteosarcoma.
Methods
Cell culture
HOS, 143B, MG63, and Saos-2 cells were purchased
from the American Type Culture Collection (ATCC,
Manassas, USA). NOS-1 was purchased from RIKEN
cell bank (Tsukuba, Japan) [67]. Cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% FBS, penicillin (100 U/ml), and strep-
tomycin (100 μg/ml). Human osteoblast cells (NHOst)
were purchased from Sanko Junyaku (Tokyo, Japan).
Cells were cultured with OBM™ (Cambrex, East Ruther-
ford, NJ, USA) or DMEM supplemented with 10% FBS.
All cells were grown in a humidified atmosphere con-
taining 5% CO2 at 37°C.
Patient’ specimens
All human osteosarcoma biopsy specimens were
obtained from primary lesions. Biopsy was performed
before chemotherapy or radio therapy for diagnostic
purpose. Normal bone tissue was obtained from femur
during total hip arthroplasty. The study protocol was
approved by the institutional review board of the
Kagoshima University. All patients and controls gave
written informed consent.
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Cells were incubated with substrate for MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
for 4 h, and washed with PBS and lysed to release forma-
zan from cells. Then cells were analyzed in a Safire
microplate reader (BIO-RAD, Hercules, CA, USA) at 562
nm. Cyclopamine and tomatidine was purchased from
Funakoshi (Tokyo, Japan). 143B cell were serum starved
for 12 h, and then cultured with recombinant human
sonic hedgehog (R&D Systems, Minneapolis, Japan).
SMO shRNA was purchased from SABiosciences
(Maryland, USA). SMO and control shRNAs were
cloned into pGeneClip™ Neomycin Vector, which
express shRNA under the control of the U1 promoter.
Lipofection of shRNA was performed every other day as
recommended in the supplier’sp r o t o c o lu s i n gF u G E N E
6 (Roche, Basel, Switzerland).
Colony formation assay
Colony formation assay was performed as previously
described [68]. Briefly, cells were suspended in DMEM
containing 0.33% agar and 10% fetal bovine serum and
plated onto the bottom layer containing 0.5% agar. The
cells were plated at a density of 5 × 10
3 per well in a
24-well plate, and colonies were counted 14 days later.
Each condition was analyzed in triplicate, and all experi-
ments were repeated three times.
Real-time PCR
All primer sets amplified 100- to 200-bp fragments. Total
RNA was extracted using the miR-Vana RNA isolation
system or TRIzol (Invitrogen, Carlsbad, CA, USA). Reac-
tions were run using SYBR Green (BIO-RAD, Hercules,
CA, USA) on a MiniOpticon™ machine (BIO-RAD, Her-
cules, CA, USA). The comparative Ct (ΔΔCt) method was
used to determine fold change in expression using bII-
microglobulin,o rGAPDH,o rACTB. Each sample was run
at three concentrations in triplicate. The following primers
were used. Desert hedgehog: 5-TGATGACCGAGCGTTG-
TAAG-3, 5-GCCAGCAACCCATACTTGTT-3; Indian
Hedgehog: 5-ACTTCTGCCTGGTCCTGTTG-3, 5-AGC-
GATCTTGCCTTCATAGC-3; Sonic hedgehog:5 - A C C G
AGGGCTGGGACGAAGA-3, 5-ATTTGGCCGCCACC-
GAGTT-3; PATCHED: 5-TAACGCTGCAACAACT-
CAGG-3, 5-GAAGGCTGTGACATTGCTGA-3; SMOOT
HENED: 5-GGGAGGCTACTTCCTCATCC-3, 5-GGCA
GCTGAAGGTAATGAGC-3; GLI1: 5-GTGCAAG
TCAAGCCAGAACA-3, 5-ATAGGGGCCTGACTGGA-
GAT-3, GLI2: 5-CGACACCAGGAAGGAAGGTA-3, 5-
AGAACGGAGGTAGTGCTCCA-3; cyclin D1: 5-ACAAA
CAGATCATCCGCAAACAC-3, 5-TGTTGGGGCTCCT
CAGGTTC-3; cyclin E1: 5-CCACACCTGACAAAGAA-
GATGATGAC-3, 5-GAGCCTCTGGATGGTGCAA-
TAAT-3; SKP2: 5-TGGGAATCTTTTCCTGTCTG-3, 5-
GAACACTGAGACAGTATGCC-3; NMYC: 5-CTTCGG
TCCAGCTTTCTCAC-3, 5-GTCCGAGCGTGTTCA
ATTTT-3; bII-microgloblin: 5-TCAATGTCGGATGGAT-
GAAA-3, 5-GTGCTCGCGCTACTC TCTCT-3; GAPDH:
5-GAAGGTGAAGGTCGGAGTC-3, 5-GAAGATGGT-
GATGGGATTTC-3; ACTB: 5-AGAAAATCTGGCAC-
CACACC-3, 5-AGAGGCGTACAGGGATAGCA-3.
Immunohistochemistry
The following primary antibodies were used; anti-SMO
(diluted 1:200, Santa Cruz, CA. U.S.A), anti-GLI2 (diluted
1:200, Abcam, Cambridge, UK), and anti-ki67 (Zymed
laboratories, San Francisco, USA). The following secondary
antibodies were used:; fluorescein-conjugated goat anti-
mouse IgG antibody (diluted 1:200; Jackson ImmunoRe-
search, PA, USA) and rhodamine-conjugated donkey anti-
rabbit IgG antibody (diluted 1:200; Chemicon, Temecula,
CA). The cells were counterstained with Hoechst 33258
(Molecular Probes, Carlsbad, CA, USA) to identify nuclei.
Immunohistochemistry with each second antibody alone
without primary antibody was performed as a control.
Western blot
Cells were lysed using NP40 lysis buffer (0.5% NP40, 10
mM Tris-HCl (pH 7.4), 150 mM NaCl, 3 mM pAPMSF
(Wako Chemicals, Kanagawa, Japan), 5 mg/ml aprotinin
(Sigma, StLouis, USA), 2 mM sodium orthovanadate
(Wako Chemicals, Kanagawa, Japan), and 5 mM EDTA).
Lysates were subjected to SDS-PAGE and subsequent
immunoblotting with antibodies to cyclin D1, E1, p21,
SKP2, and pRb (Santa Cruz, CA. U.S.A). Detection was
performed using the ECL detection system (Amersham,
Giles, UK).
Animal experiments
143B cells (1 × 10
6) were mixed with a collagen gel in a
1:1 volume, and were inoculated subcutaneously in 5-
week-old nude mice. The mice were randomly assigned
to receive either cyclopamine (25 mg/kg-10 mg/kg) or
an equal volume of DMSO as control. Cyclopamine and
saline solution were administered by intraperitoneal
injection. The treatment with cyclopamine was initiated
1 week after tumor inoculation when the tumors had
grown to visible size. The injections were repeated every
other day. Tumor size was measured with calipers
weekly, and tumor volume was calculated using a for-
mula of LW
2/2 (L and W representing the length and
width of tumors). SMO shRNA (SABiosciences, Mary-
land, USA) transfected 143B cells (1 × 10
6) or control
shRNA (1 × 10
6) cells were mixed with a collagen gel in
a 1:1 volume, and were inoculated subcutaneously in 5-
week-old nude mice. Tumor size was measured with
calipers weekly, and tumor volume was calculated using
a formula of LW
2/2 (L and W representing the length
and width of tumors). All experimental procedures were
performed in compliance with the guiding principles for
the Care and Use of Animals described in the American
Journal of Physiology and with the Guidelines estab-
lished by the Institute of Laboratory Animal Sciences,
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Page 11 of 14Faculty of Medicine, Kagoshima University. All efforts
were made to minimize animal suffering, to reduce the
number of animals used, and to utilize possible alterna-
tives to in vivo techniques.
Cell cycle analysis
Cell cycle analysis was performed by Reprocell (Tokyo,
Japan). At 48 h after cyclopamine treatment, cells were
collected by trypsinization and washed with DPBS. Cells
were fixed in 70% (v/v) ethanol at 4°C, washed with PBS,
and resuspended with 500 μl of staining solution [PBS
pH 7.4, 100 μg/ml DNase-free RNase, 1 mg/ml propi-
dium iodide]. Cells were then analyzed by flow cytometry
using a FACS Vantage SE (Becton Dickinson, Franklin
Lakes, NJ). Data were gated using pulse width and pulse
area to exclude doublets, and the percentage of cells pre-
sent in each phase of the cell cycle was calculated using
FlowJo software (Tree Star, Ashland, OR, USA).
Statistics and supplemental data
Each sample was analyzed in triplicate, and experiments
were repeated three times. In all figures, error bars are
standard divisions. All statistical analyses were per-
formed using Microsoft Office Excel (Microsoft, Albu-
querque, New Mexico, USA) and STASTISCA (StatSoft,
Tulsa, OK, USA). Differences between mean values were
evaluated by the unpaired t-test, and differences in fre-
quencies by Fisher’s exact test. Differences were consid-
ered significant at P < 0.05.
List of abbreviations
(Hh): Hedgehog; (SMO): SMOOTHENED; (PTCH1):
PATCHED; (SHH): Sonic hedgehog; (DHH): Desert
hedgehog.
Additional file 1: A, Immunohistochemical examination revealed
that SMO was expressed on cytoplasm of 143B and GLI2 was
localized in the nucleus of 143B. B, MTT assay showed that Sonic
hedgehog promote proliferation of osteosarcoma cells. The experiment
was triplicate with similar results.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-5-
S1.TIFF]
Additional file 2: Real-time PCR was performed to quantify mRNAs
of cell cycle related genes.SMO shRNA reduced levels of cyclin D1,
cyclin E1, SKP2, and E2F1 transcription (error bar means S.D.). The
comparative Ct (ΔΔCt) method was used to determine fold change in
expression using ACTB. The experiment was triplicate with similar results.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-5-
S2.TIFF]
Additional file 3: We performed real-time PCR using formed
tumors. Real-time PCR revealed that transcription of GLI1, GLI2, and
PTCH1 was decreased in tumors formed by SMO shRNA-transfected 143B.
In addition, SMO shRNA reduced levels of Cyclin E1, SKP2,a n dE2F1
transcription. The comparative Ct (ΔΔCt) method was used to determine
fold change in expression using ACTB. The experiment was triplicate with
similar results.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-5-
S3.TIFF]
Additional file 4: Cyclopamine prevents proliferation of
osteosarcoma in vivo. Immunohistochemical examination of ki67 was
performed in xenograft tumors. Ki67 staining revealed that proliferation
of osteosarcoma cells was decreased by cyclopamine treatment. The
numbers of Ki67-positive cells was decreased to 50% of control revel by
cyclopamine administration at day 14 (error bar means S.D.).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-5-
S4.TIFF]
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